An Investigation Into Local Infusion Site Pain After Infusion of Ultra Rapid Lispro Excipients Across Sites and Depths
Authors' conclusion
Local infusion site discomfort after infusion of URLi excipients was reported by a small subset of participants; it was transient, tolerable, and dependent on infusion site but not infusion depth. Given differences within individuals, patients may consider using a different infusion site if they experience discomfort.
Study context
- Population
- Adults with T1D on CSII; mean age 40.5 years, BMI 27.5
- Participants
- 40 adults
- Comparison
- Infusion of ultra rapid lispro (URLi) excipients across infusion sites and depths
- Primary endpoint
- Local infusion site pain on 0–100 mm VAS after 15 unit-equivalent boluses (150 μL) of URLi excipients
- Follow-up
- 5 min pre-bolus, 1 and 15 min post-bolus
Methodological detailsphase 1, one-day, five-period crossover
- Phase 1
- One-day
- Five-period crossover
Primary result
As reported in the abstract
Infusion site pain (VAS) · 1 min post-bolus
Scores >45 mm (clinically meaningful pain)
7 of 577
Further findings
Infusion site pain (visual analog scale (VAS)) · 15 min post-bolus
- VAS scores returned to pre-bolus levels
Original publication
An Investigation Into Local Infusion Site Pain After Infusion of Ultra Rapid Lispro Excipients Across Sites and Depths. J Diabetes Sci Technol. Published 3 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →